Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Total Non-Current Liabilities of $134.6 million for Q1 2026, down 9.95% on a QoQ basis from $149.5 million in Q4 2025, and up 17.76% year-over-year from $114.3 million in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $134.6 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 17.76% year-over-year to $134.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.6 million (up 17.76% YoY) and the FY2025 annual result came in at $149.5 million, up 21.09% from the prior year.
- Total Non-Current Liabilities was $134.6 million for Q1 2026 at Catalyst Pharmaceuticals, down from $149.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $149.5 million in Q4 2025 and bottomed at $48.3 million in Q3 2022.
- A 5-year average of $94.7 million and a median of $95.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 97.52% — and 2026, when it grew 17.76%.
- Catalyst Pharmaceuticals' Total Non-Current Liabilities stood at $61.1 million in 2022, then increased by 29.61% to $79.3 million in 2023, then soared by 55.79% to $123.5 million in 2024, then grew by 21.09% to $149.5 million in 2025, then declined by 9.95% to $134.6 million in 2026.
- Business Quant data shows CPRX's Total Non-Current Liabilities at $134.6 million in Q1 2026, $149.5 million in Q4 2025, and $131.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 134.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.63 Mn |
| Dec 31, 2025 | 149.50 Mn |
| Sep 30, 2025 | 131.20 Mn |
| Jun 30, 2025 | 115.58 Mn |
| Mar 31, 2025 | 114.33 Mn |
| Dec 31, 2024 | 123.46 Mn |
| Sep 30, 2024 | 108.28 Mn |
| Jun 30, 2024 | 95.31 Mn |
| Mar 31, 2024 | 82.66 Mn |
| Dec 31, 2023 | 79.25 Mn |
| Sep 30, 2023 | 61.09 Mn |
| Jun 30, 2023 | 55.88 Mn |
| Mar 31, 2023 | 60.18 Mn |
| Dec 31, 2022 | 61.15 Mn |
| Sep 30, 2022 | 48.32 Mn |
| Dec 31, 2021 | 30.96 Mn |
| Dec 31, 2019 | 24.75 Mn |
| Jun 30, 2019 | 14.15 Mn |
| Mar 31, 2019 | 9.90 Mn |
| Dec 31, 2018 | 9.51 Mn |